Gilad Oren Insider Trades

Insider Trading History

Track insider trading activity for Gilad Oren. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Aprea Therapeutics
Aprea Therapeutics APRE
President/ceo
Holding Value $305k 393,895 shares
Last Trade
Mar 12, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$77.2k 100,875 shares
$0.76
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President/ceo
Holding Value $290k 373,720 shares
Last Trade
Jan 30, 2026 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$46.6k 56,200 shares
$0.83
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President/ceo
Holding Value $16.6k 21,459 shares
Last Trade
Dec 10, 2025 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$40.4k 42,918 shares
$0.94
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President/ceo
Holding Value $268k 345,620 shares
Last Trade
Apr 03, 2025 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$10.1k 5,500 shares
$1.84
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President/ceo
Holding Value $264k 340,120 shares
Last Trade
Mar 27, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$59.2k 26,900 shares
$2.20
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President/ceo
Holding Value $258k 333,395 shares
Last Trade
Oct 23, 2024 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$1.96k 500 shares
$3.92
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President/ceo
Holding Value $258k 332,895 shares
Last Trade
Oct 15, 2024 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$725 250 shares
$2.90
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President/ceo
Holding Value $258k 332,645 shares
Last Trade
Oct 14, 2024 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$2.59k 1,000 shares
$2.59
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President/ceo
Holding Value $257k 331,645 shares
Last Trade
Oct 10, 2024 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$381 150 shares
$2.54
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President, CEO
Holding Value $257k 331,495 shares
Last Trade
Mar 28, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$180k 26,900 shares
$6.69
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President, CEO
Holding Value $252k 324,770 shares
Last Trade
Mar 13, 2024 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$22.2k 4,000 shares
$5.55
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President, CEO
Holding Value $250k 322,770 shares
Last Trade
Mar 09, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$81.3k 16,000 shares
$5.08
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President, CEO
Holding Value $0 0 shares
Last Trade
Aug 23, 2022 Sale (Conversion)Shares acquired or disposed through conversion of a derivative or other security.
$10.4M 604,510 shares
$17.20
$0.78
Aprea Therapeutics
Aprea Therapeutics APRE
President, CEO
Holding Value $4.94M 6,375,414 shares
Last Trade
Aug 23, 2022 Purchase (Conversion)Shares acquired or disposed through conversion of a derivative or other security.
$104M 6,045,100 shares
$17.20
$0.78

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up